3-(methylsulfonyl)benzene-1,2-diamine | 148278-73-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(methylsulfonyl)benzene-1,2-diamine
• 英文别名: 3-(Methylsulfonyl)-1,2-benzenediamine；3-methylsulfonylbenzene-1,2-diamine
• CAS: 148278-73-3
• 化学式: C₇H₁₀N₂O₂S
• 分子量: 186.235
• InChiKey: ZAIQAMUPQDZCCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• HETEROCYCLIC COMPOUNDS AND THEIR USES
  申请人：Cushing Timothy D.

  公开号：US20110245257A1

  公开（公告）日：2011-10-06

  Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  含有替代双环杂环芳基的化合物及其组合物，用于治疗一般性炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定的膀胱疾病、牛皮癣、具有炎症成分的皮肤疾病、慢性炎症性疾病，包括但不限于自身免疫疾病，如系统性红斑狼疮（SLE）、重症肌无力、类风湿关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化、Sjögren综合征和自身免疫性溶血性贫血，以及包括所有形式的过敏反应的过敏症状。本发明还提供了治疗依赖于或与p110δ活性相关的癌症的方法，包括但不限于介导的白血病，如急性髓细胞白血病（AML）、骨髓增生异常综合征（MDS）、骨髓增生性疾病（MPD）、慢性髓细胞白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体肿瘤，如乳腺癌。
• [EN] NOVEL SUBSTITUTED HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROAROMATIQUES SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA STÉAROYL-COENZYME A DELTA-9 DÉSATURASE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2009129625A1

  公开（公告）日：2009-10-29

  Substituted heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; Type 2 diabetes; insulin resistance; hyperglycemia; Metabolic Syndrome; neurological disease; cancer; and liver steatosis. Formula (I).

  结构式I的替代杂环芳香化合物是硬脂酰辅酶A Δ-9 脱饱和酶的抑制剂。本发明的化合物对预防和治疗与异常脂质合成和代谢相关的疾病条件具有用处，包括心血管疾病，如动脉粥样硬化；肥胖；2 型糖尿病；胰岛素抵抗；高血糖；代谢综合征；神经疾病；癌症；和肝脂肪变性。公式（I）。
• Selective sulfonation process
  申请人：ELI LILLY AND COMPANY

  公开号：EP0093591A1

  公开（公告）日：1983-11-09

  4-acyl-o-phenylenediamine is selectively sulfonated on the amino group meta to the acyl group to provide an important intermediate for benzimidazole pharmaceuticals. Some of the intermediates are new to organic chemistry.

  4-acyl-o-phenylenediamine 的氨基元与酰基发生选择性磺化反应，为苯并咪唑类药物提供了一种重要的中间体。其中一些中间体在有机化学中是全新的。
• NOVEL SUBSTITUTED HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Merck Frosst Canada Ltd.

  公开号：EP2279177A1

  公开（公告）日：2011-02-02
• US3978040A
  申请人：——

  公开号：US3978040A

  公开（公告）日：1976-08-31